STOCK TITAN

Athira Pharma Inc - ATHA STOCK NEWS

Welcome to our dedicated news page for Athira Pharma (Ticker: ATHA), a resource for investors and traders seeking the latest updates and insights on Athira Pharma.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Athira Pharma's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Athira Pharma's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.41%
Tags
conferences earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.35%
Tags
conferences clinical trial
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.43%
Tags
clinical trial
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.64%
Tags
conferences clinical trial
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.64%
Tags
clinical trial
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3%
Tags
management
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.15%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.3%
Tags
earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.13%
Tags
none
Athira Pharma Inc

Nasdaq:ATHA

ATHA Rankings

ATHA Stock Data

98.12M
26.94M
2.19%
62.86%
2.04%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States
Bothell

About ATHA

m3 biotechnology is an innovative therapeutics company that has a novel platform of disease-modifying regenerative small molecules, particularly relevant to neurodegenerative diseases. the lead compound modifies growth-factor systems, where the activation is expected to stop disease progression and even restore lost function. the company’s research has been funded by the alzheimer’s drug discovery foundation, washington’s life sciences discovery fund, w fund, wrf capital, dolby family ventures and other private investors. where current and emerging therapies are focused primarily on disease symptoms and improving the quality of life of patients suffering from disease, m3 differentiates itself from the competition by addressing the neurodegenerative process, providing a cost-effective solution and feasible delivery mechanism. our strategy is to leverage our patented and proprietary technologies to develop small molecule modulators with a primary focus on altering the course of alzheimer